Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes
Saved in:
| Published in: | ACR Open Rheumatology |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes
- Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists
- From Nerve to Autoimmunity: Acute Guillain-Barré Syndrome in a 4-Year-Old with Early-Onset Pediatric Systemic Lupus Erythematosus
- Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease
- Association of autoimmune diseases with biologic agents targeting type 2 immunity: An observational study using a claims database
- Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity
- Unmet needs in patients with RA judged in remission by the rheumatologist: a semi-structured interview study